A pioneering initiative is making headlines with its ambitious goal to reverse peanut allergies in infants under twelve months. The National Allergy Centre of Excellence (NACE), based at the Murdoch Children’s Research Institute (MCRI), is spearheading this world-first program in partnership with ten pediatric hospitals across five Australian states.
Revolutionizing Allergy Care
The ADAPT OIT Program marks the first nationwide effort to provide standardized oral immunotherapy (OIT) for peanut allergies outside of a clinical trial setting. This innovative program aims to induce remission and transform the management of peanut allergies in young children.
The treatment involves a carefully structured daily regimen of peanut powder administered at home over a two-year period. Children enrolled in the program will follow a precise dosing schedule, with support from a comprehensive action plan that includes an anaphylaxis action plan and an adrenaline injector. Families will also have continuous access to an allergist for any necessary guidance.
A Coordinated Approach to Allergy Treatment
Dr. Tim Brettig, a pediatric allergist, immunologist, and the medical lead for the ADAPT OIT Program, emphasizes the importance of medical supervision throughout the treatment process. “We administer a daily dose of the allergen that is initially below the reaction threshold, gradually increasing the dose under medical supervision to build tolerance,” explains Dr. Brettig. He notes that research supports the effectiveness of this approach in managing food allergies.
Addressing a Growing Epidemic
Australia is known as the allergy capital of the world, with peanut allergies being particularly prevalent among children. Research led by MCRI indicates that 3.1% of Australian infants aged twelve months suffer from peanut allergies. Dr. Brettig highlights the urgent need for such programs, given the increasing burden of food allergies on the healthcare system and the quality of life for affected families.
“Nut allergies are a significant cause of morbidity and mortality, with rising cases of allergic reactions leading to more emergency department visits,” says Dr. Brettig. “Improving quality of life for these children involves not only effective treatment but also reducing the constant worry of allergic reactions.”
A National Collaboration
The ADAPT OIT Program stands out for its unique, nationally coordinated approach. While countries like the US, Canada, and various European nations have implemented immunotherapy programs, their methodologies differ. The ADAPT OIT Program aims to standardize treatment across ten participating hospitals, allowing for a comprehensive assessment of outcomes on a national scale.
Dr. Brettig expresses his admiration for the collaborative effort involved in this program. “The coordination among hospital departments, OIT specialists, nursing staff, and various advisory groups has been remarkable. This collective effort is driven by a shared commitment to improving the lives of children with peanut allergies.”
Commitment and Safety
Participating families will need to commit to the daily regimen of allergen dosing, supported by rigorous safety measures to minimize risks. In addition to the action plan and education pack provided, families will benefit from expert guidance throughout the program.
Dr. Brettig underscores the significance of this initiative. “Food allergies present a major challenge today, and this program represents a significant step towards addressing that issue and improving outcomes for affected children.”
The program’s availability is limited to children treated at the ten participating hospitals, with capacity dependent on demand and resources.
[inline_related_posts title=”You Might Be Interested In” title_align=”left” style=”list” number=”6″ align=”none” ids=”11396,11305,11301″ by=”categories” orderby=”rand” order=”DESC” hide_thumb=”no” thumb_right=”no” views=”no” date=”yes” grid_columns=”2″ post_type=”” tax=””]
